ReviewWorld journal of gastroenterology2013
Probiotics and irritable bowel syndrome.
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.BMC gastroenterology · 2016Pooled it
- Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.World journal of gastroenterology · 2015Pooled it
- Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial.Scientific reports · 2024Trial
- Bacillus Subtilis (BG01-4Nutrients · 2023Trial
- Trial
- Evaluation of Health-Related Quality of Life in Patients Treated with Synbiotics: a Prospective Observational Study.Maedica · 2026Article
- Initiating multi-strain probiotics is associated with clinically meaningful symptom relief, better quality of life, and fewer treatment escalations in IBS-D/IBS-M: a Chinese real-world propensity-matched cohort study.Frontiers in medicine · 2026Article
- Article
- Sex Difference in the Effect ofJournal of cancer prevention · 2024Article
- The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment.World journal of gastroenterology · 2023Review
- Prospective Use of Probiotics to Maintain Astronaut Health during Spaceflight.Life (Basel, Switzerland) · 2023Review
- Yeast Genomics and Its Applications in Biotechnological Processes: What Is Our Present and Near Future?Journal of fungi (Basel, Switzerland) · 2022Review
- Supplementation with CombinedMicroorganisms · 2020Article
- Lactobacillus plantarum PS128 Ameliorated Visceral Hypersensitivity in Rats Through the Gut-Brain Axis.Probiotics and antimicrobial proteins · 2020Article
- Article
- Targeting the gut microbiota for the treatment of irritable bowel syndrome.The Kaohsiung journal of medical sciences · 2020Review
- Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk.Journal of clinical medicine · 2019Review
- Review
- Sex-Gender Differences in Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is common gastrointestinal problems. It is characterized by abdominal pain or discomfort, and is associated with changes in stool frequency and/or consistency. The etiopathogenesis of IBS may be multifactorial, as is the pathophysiology, which is attributed to alterations in gastrointestinal motility, visceral hypersensitivity, intestinal microbiota, gut epithelium and immune function, dysfunction of the brain-gut axis or certain psychosocial factors. Current therapeutic strategies are often unsatisfactory. There is now increasing evidence linking alterations in the gastrointestinal microbiota and IBS. Probiotics are living organisms which, when ingested in certain numbers, exert health benefits beyond inherent basic nutrition. Probiotics have numerous positive effects in the gastrointestinal tract. Recently, many studies have suggested that probiotics are effective in the treatment of IBS. The mechanisms of probiotics in IBS are very complex. The purpose of this review is to summarize the evidence and mechanisms for the use of probiotics in the treatment of IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.